Pertuzumab

Overview

Pertuzumab, sold under the brand name Perjeta among others, is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer.[1] WP

Side effects in more than half the people taking it include diarrhea, hair loss, and loss of neutrophils; more than 10% experience loss of red blood cells, hypersensitivity or allergic reaction, infusion reactions, decreased appetite, insomnia, distortions in the sense of taste, inflammation of the mouth or lips, constipation, rashes, nail disease, and muscle pain. Women who are pregnant or planning on getting pregnant should not take it, it was not studied in people with certain heart conditions and should be used in caution in such people, and it should not be used with an anthracycline. It is unknown if pertuzumab interacts with doxorubicin.[2] WP

It is the first-in-class of a kind of medication called a "epidermal growth factor receptor (HER) dimerization inhibitor" — it inhibits the dimerization of HER2 with other HER receptors, which prevents them from signalling in ways that promote cell growth and proliferation.[3] WP

It was discovered and developed by Genentech and was first approved in 2012.[4][5] WP

Drug class

Antineoplastic WP

From the Wikipedia article's infobox.

Uses, dosage and effects

Medical uses

Pertuzumab, along with trastuzumab (Herceptin), docetaxel (Taxotere), and carboplatin, is given as intravenous (IV) infusions for the treatment of early stage, HER-positive breast cancer. Pertuzumab, in combination with trastuzumab and docetaxel, are given as a first line treatment for HER2-positive metastatic breast cancer.[1][2][6] WP

Women of child-bearing age should use contraception while taking pertuzumab; it may damage the fetus in pregnant women, and it may be secreted in breast milk.[2] WP

Risks and side effects

Adverse effects

In clinical trials of the three-agent combination therapy in metastatic breast cancer, adverse effects occurring in more than half the people taking it included diarrhea, hair loss, and loss of neutrophils; more than 10% of people experienced loss of neutrophils with fever, and loss of leukocytes. After docetaxel was dropped in some people, the most common adverse effects were diarrhea (28.1%), upper respiratory tract infection (18.3%), rash (18.3%), headache (17.0%), fatigue (13.4%), swelling of nasal passages and throat (often due to catching the common cold) (17.0%), weakness (13.4%), itchiness (13.7%), joint pain (11.4%), nausea (12.7%), pain in an extremity (13.4%), back pain (12.1%) and cough (12.1%).[2] WP

In clinical trials of the neoadjuvant use of the combination, more than 50% of people had hair loss and loss of neutrophils.[2] WP

In both uses, more than 10% of people additionally experienced: loss of red blood cells, hypersensitivity or allergic reaction, infusion reactions, decreased appetite, insomnia, distortions in the sense of taste, inflammation of the mouth or lips, constipation, rashes, nail disease, and muscle pain.[2] WP

Pharmacology

Pharmacology

The metabolism of pertuzumab has not been directly studied; in general antibodies are cleared principally by catabolism. The median clearance of pertuzumab was 0.235 liters/day and the median half-life was 18 days.[2] WP

Mechanism of action

HER2 is an extracellular receptor—a receptor tyrosine kinase - that when activated, sets off signal transduction through several pathways that stimulate cell proliferation and cell growth; if overexpressed it can cause uncontrollable growth. HER2 positive breast cancer is caused by ERBB2 gene amplification that results in overexpression of HER2 in approximately 15-30% of breast cancer tumors.[7] WP

HER2 normally combines another protein in order to function (a process called dimerization); it can bind with a second HER2 receptor (acting as a homodimer) and it can heterodimerize with a different receptor of the HER family. The most potent dimer for activating signalling pathways is HER2/HER3.[3] WP

The epitope for pertuzumab is the domain of HER2 where it binds to HER3, and pertuzumab prevents the HER2/HER3 dimer from forming, which blocks signalling by the dimer. Trastuzumab is another monoclonal antibody against HER2; its epitope is the domain where HER2 binds to another HER2 protein. The two mAbs together prevent HER2 from functioning.[3][8] WP

History

History

The monoclonal antibody 2C4 appears to have first been published in 1990 by scientists from Genentech, the same year that F. Hoffmann-La Roche AG acquired a majority stake in Genentech.[9][10][11] WP

By 2003, Genentech understood that 2C4 prevented HER2 dimerizing with other HER receptors and had begun Phase I trials, aiming for a broad range of cancers, not just ones overexpressing HER2. It was the first known HER dimerization inhibitor.[12] WP

In 2005, Genentech presented poor results of Phase II trials of pertuzumab as a single agent in prostate, breast, and ovarian cancers, and said that it intended to continue developing it in combination with other drugs for ovarian cancer.[13][14] WP

In 2007, Genentech dropped the trade name Omnitarg.[15][16] WP

In March 2009, Roche acquired Genentech.[17][18] WP

In 2012, the results were published of the CLEOPATRA trial, a randomized placebo-controlled Phase III trial of pertuzumab in combination with trastuzumab and docetaxel in HER2-positive metastatic breast cancer. Pertuzumab received US FDA approval for the treatment of HER2-positive metastatic breast cancer later that year. Results of a Phase II trial in the neoadjuvant setting, NeoSphere, published in 2012, and results of a Phase II cardiac safety study in the same population, Tryphaena, published in 2013. The FDA approved the neoadjuvant indication in 2013.[5][19–23] WP

Pertuzumab was approved for medical use in the European Union in 2013.[2][24] WP

Aphinity study

The phase III APHINITY study demonstrated statistically significant long-term survival benefits for people with HER2-positive early-stage breast cancer. After ten years, individuals treated with pertuzumab, trastuzumab and chemotherapy (the pertuzumab-based regimen) showed a 17% reduction in the risk of death compared to those receiving trastuzumab, chemotherapy, and placebo as adjuvant therapy.[25][26] WP

The study showed that 91.6% of patients treated with the pertuzumab-based regimen were alive after ten years, compared to 89.8% of those receiving the placebo regimen. A clinically significant reduction in the risk of death was observed in the pre-specified subgroup of patients with lymph node-positive disease (21% reduction, HR=0.79). No benefit was observed in the node-negative subgroup.[25][26] WP

Legal status

Biosimilars

In November 2025, the biosimilar pertuzumab-dpzb (Poherdy) was approved for medical use in the United States as an interchangeable biosimilar to Perjeta. It is the first approval of a biosimilar for Perjeta.[27] WP

Economics

As of 2016, in the US each cycle of the three-drug combination given every three weeks costs around US$8,500, not including ancillary care costs.[28] WP

In the UK, a NICE evaluation in 2015, made a preliminary finding that the drug combination was not cost effective, and NICE rejected the drug in the neoadjuvant setting in May 2016, primarily because it was unknown if the drug combination provided a survival benefit. This decision was subsequently reversed six months later and pertuzumab became the first new breast cancer drug to be approved by NICE for routine NHS funding in almost a decade after Roche pledged to provide the drug to the NHS at an undisclosed discount for patients in the neoadjuvant setting and to share the long–term financial risks.[29–32] WP

Chemistry

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Perjeta- pertuzumab injection, solution, concentrate
2. Other Perjeta 420 mg Concentrate for Solution for Infusion — Summary of Product Characteristics (SmPC). 2 July 2021
3. Journal / agency Harbeck N, Beckmann MW, Rody A, Schneeweiss A, Müller V, Fehm T, Marschner N, Gluz O, Schrader I, Heinrich G, Untch M, Jackisch C. HER2 Dimerization Inhibitor Pertuzumab — Mode of Action and Clinical Data in Breast Cancer. Breast Care. March 2013. doi:10.1159/000346837 · PMID 24715843 · PMC3971793
4. Journal / agency Drug Approval Package: Perjeta (pertuzumab) Injection NDA #125409. 3 August 2012
5. Journal / agency FDA approves Perjeta for type of late-stage breast cancer. 8 June 2012
6. Other TCHP Chemo Treatment: Taxotere + Carboplatin + Herceptin + Perjeta. April 26, 2025
7. Journal / agency Mitri Z, Constantine T, O'Regan R. The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemotherapy Research and Practice. 2012. doi:10.1155/2012/743193 · PMID 23320171 · PMC3539433
8. Journal / agency Badache A, Hynes NE. A new therapeutic antibody masks ErbB2 to its partners. Cancer Cell. April 2004. doi:10.1016/s1535-6108(04)00088-1 · PMID 15093533
9. Journal / agency Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Research. March 1990. PMID 1689212
10. Journal / agency Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Research. June 2001. PMID 11406546
11. Other Fisher LM. Genentech: Survivor Strutting Its Stuff. 1 October 2000
12. Journal / agency Albanell J, Codony J, Rovira A, Mellado B, Gascón P. New Trends in Cancer for the 21stCentury. 2003. doi:10.1007/978-1-4615-0081-0_21 · PMID 12908564
13. Other Press Release: Data From Omnitarg Clinical Program Presented at American Society of Clinical Oncology Meeting. 15 May 2005
14. Other Genentech's Omnitarg fails in Phase II. 16 May 2005
15. Journal / agency Correction: Letter from the Editor. Cancer Oncology News. February 2012
16. Other Press release: Roche in the first half of 2007. 19 July 2007
17. Other Morse A. Chugai Shares Post Healthy Gain On Prospects for Cancer Drug. 10 May 2006
18. Other Roche Makes $43.7B Bid for Genentech. 21 July 2008
19. Journal / agency Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. The New England Journal of Medicine. January 2012. doi:10.1056/nejmoa1113216 · PMID 22149875 · PMC5705202
20. Journal / agency Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. The Lancet. Oncology. January 2012. doi:10.1016/s1470-2045(11)70336-9 · PMID 22153890
21. Journal / agency Mates M, Fletcher GG, Freedman OC, Eisen A, Gandhi S, Trudeau ME, Dent SF. Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Current Oncology. March 2015. doi:10.3747/co.22.2322 · PMID 25848335 · PMC4381787
22. Journal / agency Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cortés J. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Annals of Oncology. September 2013. doi:10.1093/annonc/mdt182 · PMID 23704196
23. Journal / agency FDA approves Perjeta for neoadjuvant breast cancer treatment. 30 September 2013
24. Journal / agency Perjeta EPAR. 17 September 2018
25. Other Hoffmann-La Roche. A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer. 2024-12-18
26. Other Roche's Perjeta-based breast cancer regimen shows sustained survival benefits - PMLiVE. 2025-05-14
27. Journal / agency FDA approves new interchangeable biosimilar to Perjeta. 13 November 2025
28. Journal / agency Durkee BY, Qian Y, Pollom EL, King MT, Dudley SA, Shaffer JL, Chang DT, Gibbs IC, Goldhaber-Fiebert JD, Horst KC. Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. Journal of Clinical Oncology. March 2016. doi:10.1200/jco.2015.62.9105 · PMID 26351332 · PMC5070553
29. Journal / agency Fleeman N, Bagust A, Beale S, Dwan K, Dickson R, Proudlove C, Dundar Y. Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer. PharmacoEconomics. January 2015. doi:10.1007/s40273-014-0206-2 · PMID 25138171
30. Other Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel) [ID523]. 1 September 2016
31. Other McKee S. NICE rejects Roche's breast cancer drug Perjeta. 20 May 2016
32. Other Yip A. NICE U-Turns and Backs Approval of Roche's Perjeta for HER2-Positive Breast Cancer. 22 November 2016

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0). Each value links to the exact revision it came from.